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Background: Dalbergia sissoo DC. (Family: Fabaceae) is a medium to large deciduous tree, is locally called “shishu”
in Bangladesh. It is used to treat sore throats, dysentery, syphilis, bronchitis, inflammations, infections, hernia, skin
diseases, and gonorrhea. This study evaluated the antinociceptive effect of the methanol extract of D. sissoo leaves
(MEDS) in mice.
Methods: The extract was assessed for antinociceptive activity using chemical and heat induced pain models such
as hot plate, tail immersion, acetic acid-induced writhing, formalin, glutamate, and cinnamaldehyde test models in
mice at the doses of 100, 200, and 400 mg/kg (p.o.) respectively. Morphine sulphate (5 mg/kg, i.p.) and diclofenac
sodium (10 mg/kg, i.p.) were used as reference analgesic drugs. To confirm the possible involvement of opioid
receptor in the central antinociceptive effect of MEDS, naloxone was used to antagonize the effect.
Results: MEDS demonstrated potent and dose-dependent antinociceptive activity in all the chemical and heat
induced mice models (p < 0.001). The findings of this study indicate that the involvement of both peripheral and
central antinociceptive mechanisms. The use of naloxone verified the association of opioid receptors in the central
antinociceptive effect.
Conclusions: This study indicated the peripheral and central antinociceptive activity of the leaves of D. sissoo.
These results support the traditional use of this plant in different painful conditions.
Keywords: Dalbergia sissoo, Antinociceptive, Opioid receptorsBackground
Dalbergia sissoo DC. (Family: Fabaceae) is a medium to
large deciduous tree, is commonly known as sisu, shee-
sham, tahli, tali, jag at different parts of the world and is
locally called “shishu” in Bangladesh. It is usually used to
treat sore throats, dysentery, syphilis, and gonorrhoea
[1]. It is used in conditions like blood purifier, leprosy,
headaches, bronchitis, inflammations, infections, hernia,
and skin diseases [2]. It has been also reported to use as
stimulant, astringent [3]; colorectal cancer and bacterial
infections [4]. Juice of the leaves is useful for anthelmin-
tic, eye and nose diseases. It also used in scabies,
burning sensation, scalding urine and digestive disorders
[5–8]. It is used as expectorant, anti-emetic, leucoderma,
ulcers, and gout like medicinal properties [9]. Boiled leaf* Correspondence: manna.034@gmail.com
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Isoflavones, biochanin-A, muningin, sissotrin, amyrin,
stigmasterol have been isolated from the aerial parts of
Dalbergia sissoo Roxb [11]. The stem-bark has been
reported to contain dalberjenone, dalbergin and methyl
dalbergin and a new 4-phenyl chromene, dalbergichro-
mene [12]. The mature pods contain a new isoflavone
glucoside identified as caviunin 7-0-gentiobioside [13],
isoflavone diglucoside recognize as isocaviunin 7-
0-gentiobioside [14]. The root bark of Dalbergia sissoo
contain a chalcone, 2, 3- dimethoxy-40-g, g-
dimethylallyloxy-20-hydroxychalcone; an isoflavone, 7-g,
g-dimethylallyloxy- 5-hydroxy-40-methoxyisoflavone; a
flavone, 7-hydroxy-6-methoxyflavon; a isoflavone, bio-
chanin A and rotenoid, dehydroamorphigenin [15].
Rhamnose, galactose, and glucuronic acid have been iso-
lated from the leave [16]. Compounds obtained from
Dalbergia sissoo like an isoflavone, biochanin is a potentle is distributed under the terms of the Creative Commons Attribution 4.0
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tinct estrogenic activity has been isolated from the fresh
flowers of Dalbergia sissoo. Two rare glycosides such as
kaempferol and quercetin rutinosides were isolated in a
low yield from the flowers of Dalbergia sissoo [17, 18].
Pharmacological studies have evaluated the analgesic
and anti-pyretic [19], anti-diabetic [20], anti-inflammatory
[21] and anti-diarrheal effect of the extract [22]. The plant
bark has been reported the anti-nociceptive [23], anti-
oxidant [24] and anti-spermatogenic activity [25]. The oil
extracted from wood scrapings of Dalbergia sissoo has
shown dose dependent larvicidal activity against mosqui-
toes [26]. Anti-osteogenic activity has also been performed
this crude extract of Dalbergia sissoo [27]. The plant ex-
tract has been used as an alternative to synthetic pesticides
for termite control in buildings [28]. The seeds extract has
modest analgesic and notable anti-pyretic activities [29].
The ethanolic extract of the bark of Dalbergia sissoo Roxb.
was investigated for its activity against helminthic infec-
tions [30]. In the search for the molluscicidal activity, the
plant extracts were evaluated against egg masses and
adults of Biomphalaria pfeifferi and the snail intermediate
host of Schistosoma manson in Nigeria [31]. In-vivo,
intrastriatal injection of mitochondrial toxin in rats pro-
duce excitotoxic lesions, while chronic administration of
3-NP produces excitotoxic-like lesions regionally re-
stricted to striatum in both rats and non-human primates
[32]. It prevents central nervous system damage [33].
According to the previous study, leaves and barks
of D. sissoo presented the antinociceptive properties
[19, 23]. Based on the studies, we designed and con-
ducted the present work to assess the effect of methanol
extract of D. sissoo leaves with six pain models in mice
and two mechanism of action study for possible activity.
The present research also warrants further investigation
into the complex mechanism of action of methanol
extract of D. sissoo leaves on induced antinociception.
Methods
Plant material and extraction
The fresh leaves of D. sissoo were collected from Khan-
pur, Bogra, Bangladesh in the month of June 2015. The
plant samples were then identified and authenticated by
Sarder Nasir Uddin, Senior Scientific Officer, Bangladesh
National Herbarium, Dhaka, Bangladesh. A voucher spe-
cimen number (DACB: 42317) has already been depos-
ited in the Herbarium for further reference. The fresh
leaves were dark dried for one week and grinded to a
fine powder. Powdered dried leaves (300 g) were macer-
ated with 1000 mL of methanol with occasional stirring
at 25 ± 2 °C for 3 days in a beaker. The extract was then
filtered using a Whatman No. 1 filter paper and a steril-
ized cotton filter. The solvent was completely removed
by rotary evaporator (BC-R 201 Shanghai BiochemicalEquipment Co. Ltd.) and 17.59 g extract (Yield 5.86%)
was obtained. This extract was used for the acute
toxicity and antinociceptive activity studies.
Animals
Swiss albino mice (20–25 g) were collected from the
Animal Research Branch of the International Center for
Diarrheal Disease and Research, Bangladesh (ICDDR, B).
Animals were kept under standard laboratory conditions
(room temperature: 25.0 ± 2.0 °C, relative humidity: 55–
65% and 12 h light/dark cycle) with food and water dur-
ing the adaptation period. The animals were acclimated
to the laboratory environment for a period of two weeks
prior to performing the experiments. Mice were fasted
overnight prior to the experiments. All the experimental
animals were treated following the Ethical Principles and
Guidelines for Scientific Experiments on Animals (1995)
formulated by The Swiss Academy of Medical Sciences
and the Swiss Academy of Sciences. The Ethics Commit-
tee of Stamford University Bangladesh (SUB/IAEC/
16.01) approved all experimental protocols.
Drugs and treatments
The control group orally received deionized water at the
volume of 0.1 mL/mouse 30 min before the experiments.
The positive control group intraperitoneally (i.p.)
received standard drug morphine in hot plate, and tail
immersion test at the dose of 5 mg/kg and diclofenac
sodium in acetic acid-induced writhing, formalin-
induced licking, glutamate-induced paw licking, and
cinnamaldehyde-induced licking test at the dose of
10 mg/kg 15 min before the experiments. MEDS was ad-
ministered orally at the doses of 100, 200, and 400 mg/
kg (b.w.) 30 min before the experiments. To evaluate the
involvement of opioid-mediated antinociceptive activity,
naloxone was administered (i.p.) at the dose of 2 mg/kg
15 min before morphine sulfate (5 mg/kg, i.p.) or MEDS
(100, 200, and 400 mg/kg, p.o.) administration in the hot
plate and tail immersion test. Methylene blue (20 mg/
kg) and glibenclamide (10 mg/kg) were intraperitoneally
employed 15 min before control (Equivalent volume of
deionized water, 0.1 mL/mouse, p.o.), or MEDS (100,
200, and 400 mg/kg, p.o.) administration to evaluate the
involvement of cyclic guanosine monophosphate
(cGMP) and ATP-sensitive K+ channel pathway respect-
ively. All the doses of drugs and MEDS were prepared
using deionized water.
Acute toxicity test
Acute toxicity studies were carried on mice according to
the method proposed by Ghosh, MEDS at the doses of 50,
100, 300, 1000, and 3000 mg/kg body weight were orally
administered to separate groups of the mice (n = 5) after
overnight fasting. Subsequent to administration of MEDS,
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festations like enlarged motor activity, salvation, convul-
sions, coma, and death. The observations were made at
regular intervals for 24 h. The animals were observed for
one week [34].
Phytochemical screening
The crude methanolic extract of D. sissoo (MEDS) was
qualitatively tested for the detection of alkaloids, flavo-
noids, saponins, tannins, glycosides, carbohydrates, re-
ducing sugars, proteins, glucosides, terpenoids, and
steroids following standard procedures [35].
Antinociceptive activity test
Hot plate test
The hot plate test method was employed for the purpose
of preferential assessment of possible centrally mediated
analgesic effects [36]. Mice were divided into five groups
of five mice each. Mice were treated with control
(Equivalent volume of deionized water, 0.1 mL/mouse,
p.o.), morphine as a standard drug (5 mg/kg, i.p.) or
MEDS (100, 200 and 400 mg/kg, p.o.) and was placed on
Eddy’s hot plate kept at a temperature of 52 ± 1 °C. A
cut off period of the 20s was maintained to avoid paw
tissue damage. The response in the form of forepaw lick-
ing, withdrawal symptom of the paws or jumping was
recorded at 0, 30, 60, 90, and 120 min following treat-
ment. Then, the percentage of the highest possible effect
(% MPE) was calculated using the following formula:
%MPE ¼ ½ Postdrug latencyð Þ ‐ Predrug latencyð Þ=
Cut off timeð Þ ‐ Pre‐drug latencyð Þ  100:
Tail immersion test
The tail immersion test is based upon the observation
that morphine-like drugs selectively prolongs the reac-
tion time of the typical tail withdrawal reflex in mice.
This method was used to evaluate the central mechan-
ism of analgesic activity. Here, the painful reactions in
animals were produced by the thermal incentive that is
dipping by the tip of the tail in hot water [37]. Mice
were divided into five groups consisting of five mice in
each group. According to the procedure, 1 to 2 cm of
the tail of mice pretreated with morphine (5 mg/kg, i.p.)
or MEDS (100, 200 and 400 mg/kg, p.o.) were immersed
in warm water kept constant at 54 ± 1 °C. The latency
between tail submersion and deflection of the tail was
recorded. A latency period of the 20s was maintained to
avoid tail tissue damage in mice. The latency period of
the tail-withdrawal response was taken as the indicator
of antinociception and was determined at 0, 30, 60, 90,
and 120 min after the administration of the morphineand MEDS. Then, the % MPE was calculated from using
the same formula used in hot plate test.
Acetic acid-induced writhing test
This test was performed to estimate the peripheral antino-
ciceptive activity of MEDS in chemical-induced pain. The
animals were divided into five groups (n = 5). The animals
were treated with control (Equivalent volume of deionized
water, 0.1 mL/mouse, p.o.), standard drug (Diclofenac so-
dium, 10 mg/kg, i.p.) or MEDS (100, 200 and 400 mg/kg,
p.o.) and then the writhing was induced by the injection
of 0.6% acetic acid 15 min after drug and 30 min after oral
administration of MEDS, respectively. 5 min after the in-
jection of acetic acid, the mice were observed and the
number of writhing was counted for 30 min [38]. The
contractions of the stomach, elongation of the body, twist-
ing of the trunk and pelvis finishing with the extension of
the limbs were considered as complete writhing. Antinoci-
ceptive activity was calculated as the percentage inhibition
of abdominal constriction.
Formalin test
The method was used as narrating by Santos and Calixto
and Santos et al. [39, 40] with minor modification. The
animals were arranged into five groups (n = 5). The con-
trol group received deionized water orally at the volume
of 0.1 mL/mouse 30 min before the experiments. Twenty
microliters of 2.5% formalin (in deionized water, subplan-
tar) was injected subcutaneously into the right hind paw
1 h after MEDS treatment (100, 200 and 400 mg/kg, p.o.)
and 15 min after injection of diclofenac sodium (10 mg/
kg, i.p.) of the mice. The time spent licking and biting the
injected paw was measured as an indicator of pain re-
sponse. Responses were measured for 5 min subsequent
to formalin injection (First phase, neurogenic) and 15–
30 min after formalin injection (Second phase, inflamma-
tory). Antinociceptive activity was calculated as the
percentage inhibition of licking time.
Glutamate-induced nociception
The method was used similarly to the previously de-
scribed by Beirith et al. [41]. Mice were divided into five
groups each containing five mice. A volume of 20 μL of
glutamate solution (10 μmol per paw) was injected
under the plantar surface of the right hind paw of the
mice 30 min after MEDS (100, 200 and 400 mg/kg, p.o.)
treatment, respectively and 15 min after injection of
diclofenac sodium (10 mg/kg, i.p.). The control group
received deionized water orally at the volume of 0.1 mL/
mouse 30 min before the experiments. The mice were
observed separately for 15 min following glutamate in-
jection. The number of licking of its injected paw was
indicative of nociception.
Table 1 Preliminary qualitative phytochemical screening of
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In order to provide more direct evidence, concerning
the participation of TRPA1 in the effect of the MEDS,
investigated its antinociceptive effect in cinnamaldehyde-
induced licking test in the mouse paw [42]. The experi-
mental animals were randomly divided into five groups
consisting of 5 mice in each. After an adjustment period
(20 min), 20 μl of cinnamaldehyde (10 nmol/paw) was
injected into the ventral surface of the right hind paw of
the mice 60 min after MEDS (100, 200 and 400 mg/kg,
p.o.) treatment and 15 min after injection of diclofenac
sodium (10 mg/kg, i.p.). The control group received de-
ionized water orally at the volume of 0.1 mL/mouse
30 min before the experiments. Mice were observed
from 0 to 5 min. (Neurogenic phase) and considered as
indicative of nociception.
Analysis of the possible mechanism of action of MEDS
Involvement of opioid system
The possible connection of the opioid system in the
antinociceptive effect of MEDS was examined by inject-
ing naloxone hydrochloride (2 mg/kg, i.p.), a non-
selective opioid receptor antagonist, and 15 min prior to
the administration of either morphine or MEDS (100,
200 and 400 mg/kg, p.o.). Then, the hot plate and tail
immersion latencies were measured at 0, 30, 60, 90, and
120 min with the same cut off time of the 20s for the
protection of animals [43].
Involvement of cyclic guanosine monophosphate (cGMP)
pathway
To investigate the possible involvement of cGMP path-
way to the antinociceptive effect of MEDS, mice were
pre-treated with methylene blue (20 mg/kg), a non-
specific inhibitor of nitric oxide/guanylyl cyclase, intra-
peritonially 15 min before the administration of diclofe-
nac sodium or MEDS (100, 200 and 400 mg/kg, p.o.).
Then, the nociceptive responses against 0.6% acetic acid
injection were seen for 30 min, opening from 5 min post
injection. The numbers of abdominal writhing were
counted as the symptom of pain behavior [44, 45].
Involvement of ATP-sensitive K+ channels pathway
The possible contribution of K+ channels in the antino-
ciceptive effect of MEDS was evaluated by using the
method described by Mohamad et al. with slide modifi-
cation [46]. The mice were pre-treated with glibencla-
mide (10 mg/kg), an ATP-sensitive K+ channel inhibitor,
intraperitoneally 15 min before the administration of ei-
ther diclofenac sodium or MEDS (100, 200 and 400 mg/
kg, p.o.). The mice were challenged with i.p. injection of
0.6% acetic acid, 30 min post-treatment. Subsequent the
injection of acetic acid, the mice were immediatelyplaced in a circle box and the number of writhing was
recorded for 30 min, starting from 5 min post injection.Statistical analysis
The results are presented as mean ± SEM. The statistical
analysis was performed using one-way analysis of variance
(ANOVA) followed by Dunnett’s post hoc test as appro-
priate using SPSS 18.00 software. Differences between
groups were considered significant at a level of p < 0.001.Results
Phytochemical screening
The phytochemical screening of the crude extract of D. sis-
soo revealed the presence of flavonoids, tannins, cardiac gly-
cosides, carbohydrates, proteins, and terpenoids (Table 1).Acute toxicity test
In the acute toxicity study, all mice survived and did not
manifest any sign of toxicity and abnormality at the
doses of 50–3000 mg/kg. After oral administration, there
was no behavioral or body weight changes and no
abnormal signs were observed for a period of 7 days.
Therefore, it can be indicated that MEDS has low
toxicity profile and the LD50 is more than 3000 mg/kg.Hot plate test
As presented in Fig. 1 and Table 2, MEDS showed a sig-
nificant antinociceptive effect at the doses of 200 mg/kg
and 400 mg/kg (p < 0.05). The administration of nalox-
one did not cause any significant attenuation of antinoci-
ceptive activity of MEDS. Moreover, administration of
morphine at the dose of 5 mg/kg confirmed a significant
antinociceptive effect (p < 0.01) when compared with
control group (Deionized water).
Fig. 1 Antinociceptive effect of D. sissoo leave extract, morphine and reversal effect of naloxone in hot plate test. Values are presented as mean
± SEM (n = 5). ** p < 0.01 compared with the control group (ANOVA followed by post hoc Dunnett’s test)
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The tail-immersion test results asserted significant anti-
nociceptive effect (p < 0.001) compared with control, at
the doses of 200 and 400 mg/kg. The antinociceptive ef-
fect of 100, 200, and 400 mg/ kg of MEDS were compar-
able to that of the reference drug (Fig. 2 and Table 3).
The antinociceptive activity of morphine used in this test
was antagonized by naloxone. The effect of naloxoneTable 2 Antinociceptive effect of D. sissoo leave extract, morphine a




Control 0.1 mL/mouse 5.40 ± 1.2
Morphine 5 5.82 ± 0.8
MEDS 100 5.20 ± 0.9
MEDS 200 7.80 ± 1.4
MEDS 400 8.80 ± 1.2
Treatment with
Naloxone
NLX 2 7.00 ± 0.7
NLX+ Control 2 + 0.1 mL/mouse 6.64 ± 0.7
NLX+ Morphine 2 + 5 6.20 ± 0.5
NLX+ MEDS 2 + 100 4.80 ± 0.5
NLX+ MEDS 2 + 200 7.40 ± 1.2
NLX+ MEDS 2 + 400 8.40 ± 0.8
Values are presented as mean ± SEM (n = 5). MEDS Methanolic extract of D. sissoo, N
**p < 0.01 compared with the control group (Dunnett’s test)
*p < 0.05 compared with the control group (Dunnett’s test)was not remarkable at any of the doses. A significant
antinociceptive effect was produced by morphine (p <
0.001) when compared with control group (Deionized
water).
Acetic acid-induced writhing test
The effect of administration of MEDS using the abdom-
inal constriction test in mice is shown in Fig. 3 andnd reversal effect of naloxone in hot plate test
) (% MPE) 30 min 60 min 90 min 120 min
0 7.20 ± 1.56 9.20 ± 0.86 9.60 ± 1.07 10.60 ± 1.07
































0 6.20 ± 0.58 5.20 ± 0.66 4.40 ± 0.51 4.00 ± 0.70
4 7.00 ± 0.70 7.80 ± 0.86 8.20 ± 0.86 9.00 ± 0.89

































Fig. 2 Antinociceptive effect of D. sissoo leave extract, morphine and reversal effect of naloxone in tail immersion test. Values are presented as
mean ± SEM (n = 5). *** p < 0.001 compared with the control group (ANOVA followed by post hoc Dunnett’s test)
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significantly the nociceptive effects induced by acetic
acid compared to the control group (Deionized water) at
the doses of 100, 200, and 400 mg/kg, respectively (p <
0.001). The percentage inhibition of constrictions was
calculated as 70.36% (Diclofenac sodium, 10 mg/kg),
35.18% (MEDS, 100 mg/kg), 48.53% (MEDS, 200 mg/
kg), and 67.10% (MEDS, 400 mg/kg) (Table 4).Table 3 Antinociceptive effect of D. sissoo leave extract, morphine a




Control 0.1 mL/mouse 2.16 ± 0.23
Morphine 5 2.03 ± 0.15
MEDS 100 2.20 ± 0.20
MEDS 200 3.81 ± 0.18
MEDS 400 2.26 ± 0.09
Treatment with
Naloxone
NLX 2 1.92 ± 0.13





2 + 5 2.08 ± 0.05
NLX+ MEDS 2 + 100 2.11 ± 0.14
NLX+ MEDS 2 + 200 3.59 ± 1.14
NLX+ MEDS 2 + 400 2.04 ± 0.07
Values are presented as mean ± SEM (n = 5). MEDS Methanolic extract of D. sissoo, N
*** p < 0.001 compared with the control group (Dunnett’s test)
** p < 0.01 compared with the control group (Dunnett’s test)
* p < 0.05 compared with the control group (Dunnett’s test)Formalin test
MEDS produced a dose-related inhibition of formalin-
induced nociception and caused significant inhibition of
both neurogenic (0–5 min) and inflammatory (15–
30 min) phases of formalin-induced licking test at the
doses of 100, 200, and 400 mg/kg when compared with
control group (Deionized water) (Fig. 4 and Table 5).
However, its antinociceptive effect was more pronouncednd reversal effect of naloxone in tail immersion test
PE) 30 min 60 min 90 min 120 min

































2.28 ± 0.16 2.77 ± 0.15 2.53 ± 0.16 2.37 ± 0.18


































Fig. 3 Antinociceptive effects of D. sissoo leave extract in acetic acid-induced writhing, glutamate-induced nociception and cinnamaldehyde-induced
nociception tests. All values are presented as mean ± SEM (n = 5). *** p < 0.001 compared with the control group (ANOVA followed by post hoc
Dunnett’s test)
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dium (10 mg/kg, i.p.) significantly reduced formalin-
induced nociception in both phases (p < 0.001).
Glutamate-induced nociception
The antinociceptive activity induced by oral administra-
tion of MEDS was dose-dependent. It showed that
MEDS at the doses of 100, 200, and 400 mg/kg pro-
duced significant prohibition of the glutamate-induced
nociception test (Fig. 3 and Table 6). Diclofenac sodium
(10 mg/kg) was used as a standard drug, which showed
81.11% inhibition of licking as compared to the control
group. All treatments displayed significant antinocicep-
tive activity (p < 0.001) compared together with the con-
trol group (Deionized water).
Cinnamaldehyde-induced nociception
The result of cinnamaldehyde-induced nociception
showed that administration of MEDS at 100, 200, and
400 mg/kg dose produced dose-dependent inhibition of
the cinnamaldehyde-induced neurogenic nociceptionTable 4 Antinociceptive effects of D. sissoo leave extract in
acetic acid-induced writhing test
Treatment Dose (mg/kg) Number of writhing Inhibition (%)
Control 0.1 mL/ mouse 61.4 ± 1.29
Diclofenac sodium 10 18.2 ± 2.25*** 70.36
MEDS 100 39.8 ± 1.78** 35.18
MEDS 200 31.6 ± 1.69*** 48.53
MEDS 400 20.2 ± 1.60*** 67.10
Values are presented as mean ± SEM (n = 5). MEDS Methanolic extract of
D. sissoo
*** p < 0.001 compared with the control group (Dunnett’s test)
** p < 0.01 compared with the control group (Dunnett’s test)with the percentage of inhibition of 28.62%, 47.32% and
68.32%, respectively (Fig. 3 and Table 7). Only 100 mg/
kg MEDS treatment showed no significant difference
compared with the control group (Deionized water), at
the same time as the rest showed significant antinoci-
ceptive activity (p < 0.001).
Involvement of cyclic guanosine monophosphate (cGMP)
pathway
The present results showed at the effects of 100, 200,
and 400 mg/ kg MEDS and methylene blue (20 mg/kg)
treatments. Methylene blue administration alone signifi-
cantly inhibited acetic acid-induced abdominal writhing
(Fig. 5 and Table 8). Given together, methylene blue sig-
nificantly (p < 0.001) increased MEDS (200, and 400 mg/
kg) induced antinociception compared to the control
group (Deionized water).
Involvement of ATP-sensitive K+ channels pathway
The present study seemed at the effects of 100, 200, and
400 mg/ kg MEDS and glibenclamide (10 mg/kg) treat-
ments. It was found out that glibenclamide (10 mg/kg)
administration alone did not alter abdominal writhing
count when assessed through the injection of 0.6% acetic
acid (Fig. 5 and Table 9). When given together, the anti-
nociceptive activity of MEDS was noticeably decreased
by glibenclamide at the doses of 200, and 400 mg/kg,
respectively.
Discussion
The study investigated the antinociceptive activity of
MEDS in classical pharmacological models of pain. The
findings of this study specify the peripheral and central
antinociceptive effect of MEDS at different doses in mice
Fig. 4 Antinociceptive effects of D. sissoo leave extract in formalin-induced nociception. Values are presented as mean ± SEM (n = 5). *** p < 0.001
compared with the control group (ANOVA followed by post hoc Dunnett’s test)
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dependently enhanced by MEDS (p < 0.05) at different
doses suggest that the central antinociceptive activity of
MEDS (Fig. 1 and Table 2). The effect is further sup-
ported by the results viewed in the tail immersion test
(Fig. 2 and Table 3), as the tail removal response in hot
water-induced pain is selective just for centrally acting
analgesics, while the peripherally acting agents are in-
active [47]. The results obtained from these two models
suggest that antinociceptive effect of MEDS was reversed
by naloxone, a non-selective opioid receptor antagonist,
against the antinociceptive effect of MEDS. The central
antinociceptive effect of MEDS may arise through opioid
receptors of spinal as well as a supraspinal system. Both
tail immersion and hot plate tests are based on measur-
ing the response of the animal to thermal stimuli where
the tail immersion check a spinal reflex, and the hotTable 5 Antinociceptive effects of D. sissoo leave extract in formalin
Treatment Dose (mg/kg) Licking of the hind paw
Early phase (0–5 min)
Control 0.1 mL/ mouse 95.40 ± 1.33
Diclofenac sodium 10 27.80 ± 2.73***
MEDS 100 66.20 ± 1.98*
MEDS 200 52.40 ± 0.87*
MEDS 400 34.80 ± 1.20*
Values are presented as mean ± SEM (n = 5). MEDS Methanolic extract of D. sissoo
*** p < 0.001 compared with the control group (Dunnett’s test)
* p < 0.05 compared with the control group (Dunnett’s test)plate is used for supraspinal reflex [48]. Reach an agree-
ment with this suggestion that μ2- and δ-opioid recep-
tors are involved in spinal mechanism, while μ1/μ2-
opioid receptors may mediate principally supraspinal
analgesia [49]. This clearly suggests that the involvement
of the activation of opioid receptors in the antinocicep-
tive action of MEDS.
In the acetic acid-induced writhing test, a dose-
dependent antinociceptive effect was observed after oral
administration of MEDS (Fig. 3 and Table 4). This test has
been used as a screening tool for assessing of the central
and peripheral antinociceptive activity [50]. In general,
acetic acid causes pain by liberating endogenous sub-
stances such as serotonin histamine, prostaglandins (PGs),
bradykinins and substance P. Local peritoneal receptors
are postulated to be occupied in the abdominal constric-
tions response [51]. Intraperitoneal administration of-induced nociception
Inhibition (%) Late phase (15–30 min) Inhibition (%)
– 41.80 ± 2.15 –
70.86 6.60 ± 0.51*** 84.21
30.60 14.60 ± 1.75*** 65.05
45.07 12.00 ± 1.00*** 71.29
63.52 08.20 ± 0.73*** 80.38
Table 6 Antinociceptive effects of D. sissoo leave extract in
glutamate-induced nociception
Treatment Dose (mg/kg) Licking time (s) Inhibition (%)
Control 0.1 mL/ mouse 82.60 ± 1.72 –
Diclofenac sodium 10 15.60 ± 1.08*** 81.11
MEDS 100 50.00 ± 1.61*** 39.46
MEDS 200 37.00 ± 1.30*** 55.20
MEDS 400 18.60 ± 1.36*** 77.48
Values are presented as mean ± SEM (n = 5). MEDS Methanolic extract of
D. sissoo
*** p < 0.001 compared with the control group (Dunnett’s test)
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lipoxygenase (LOX), prostaglandins (PGs), histamine,
serotonin, bradykinin, substance P, IL-1β, IL-8,TNF-α in
the peripheral tissue fluid. These mediators cause the
stimulation of primary afferent nociceptors entering dorsal
horn of the central nervous system [52]. The release of
these inflammatory mediators is thought to contribute to
increased blood-brain barrier (BBB) permeabilization or
interruption [53]. Moreover, injection of pain inducing
agent like acetic acid is also responded to enhance vaso-
dilation and vascular fluid permeability and these events
were reversed by plant extracts [54]. From a mechanistic
point of view, the lack of specificity in acetic acid-induced
writhing test suggesting the participation of different noci-
ceptive mechanisms in the reduction of muscular con-
striction such as sympathetic system throughout the
release of biogenic amines, cyclooxygenases and their
metabolites inhibition and through opioid receptors
mechanisms [55]. Therefore, the inhibition of writhing
response in the present study clearly indicated the periph-
eral antinociceptive effect of MEDS in addition to its
central effect.
Formalin-induced test is a pain-related licking re-
sponse of the injected paw in two distinct phases. The
first phase is presented by neurogenic pain caused by
direct chemical stimulation of nociceptors. The second
phase is marked by inflammatory pain triggered by a fu-
sion of stimuli-inflammation of the peripheral tissues
and mechanisms of central sensitization. In this latter
part, different mediators are involved, as excitatoryTable 7 Antinociceptive effects of D. sissoo leave extract in
cinnamaldehyde-induced nociception
Treatment Dose (mg/kg) Licking time (s) Inhibition (%)
Control 0.1 mL/ mouse 52.40 ± 1.54
Diclofenac sodium 10 13.80 ± 1.53*** 73.66
MEDS 100 37.40 ± 0.93 28.62
MEDS 200 27.60 ± 1.66*** 47.32
MEDS 400 16.60 ± 1.86*** 68.32
Values are presented as mean ± SEM (n = 5). MEDS Methanolic extract of
D. sissoo
*** p < 0.001 compared with the control group (Dunnett’s test)amino acids, neuropeptides, nitric oxide, PGE2, and ki-
nins [56]. Our present results showed that the number
of paw licking was significantly reduced by MEDS in
both neurogenic and inflammatory pain responses (p <
0.001) in a dose dependant manner (Fig. 4 and Table 5).
However, the effect was more assert in the late phase.
Centrally acting analgesic drugs inhibit both the phases
of formalin test, while peripherally acting analgesics re-
strict only the late phase responses. Diclofenac sodium
significantly suppressed the late phase pain response.
The first phase finding of formalin test further confirms
the central antinociceptive effect of MEDS that we have
observed in the hot plate and tail immersion tests. The
late phase response as the antinociceptive effect
observed in acetic acid-induced writhing test is due to
this inhibition of the inflammatory mediators [57].
Phytochemical screening exposed that flavonoids,
tannins, cardiac glycosides, carbohydrates, proteins, and
terpenoids are present in D. sissoo. The MEDS showed
significant and dose-dependent antinociceptive activity
due to the presence of flavonoids [23]. Flavonoids have
been found to suppress the intracellular Ca2+ ion eleva-
tion in a dose-dependent manner, as well as possible the
release of proinflammatory mediators such as TNF-α
[58]. Flavonoids may enhance the amount of endogen-
ous serotonin or may act together with 5-HT2 and
5-HT3 receptors, which may be involved in the mechan-
ism of central pain reliever activity [59]. There are also
reports on the role of flavonoid in analgesic activity prin-
cipally by targeting prostaglandins [60]. Moreover,
MEDS showed significant analgesic activity in the whole
experimental model, which may be due to its high fla-
vonoid. Furthermore, flavonoids have the capability to
inhibit ecosanoid biosynthesis. Ecosanoids, such as pros-
taglandins are involved in different immunological
responses and are the products of the cyclooxygenase
and lipoxygenase pathways [61]. Tannins are also
invented to have a contribution in antinociceptive activ-
ity [62]. Therefore, it can be agreed that cyclooxygenase
(COX) inhibitory activity alongside with antioxidant
activity may reduce the production of arachidonic acid
from phospholipids or may reduce the enzyme system
responsible for the synthesis of prostaglandins and
finally relieve pain-sensation.
In another experiment to determine the role of the
glutamatergic system in the modulation of MEDS anti-
nociception, the extract was treated with the glutamate-
induced paw-licking test. Previous reports have shown
that the glutamate and glutamatergic receptors are very
important in the peripheral, spinal, and supraspinal noci-
ceptive neurotransmission [63–65], which is greatly
mediated by both N-methyl-D-aspartate (NMDA) and
non-NMDA receptors, as well as possible by the release
of nitric oxide and nitric oxide-related substances [41].
Fig. 5 Effects of D. sissoo leave extract on involvement of cyclic guanosine monophosphate (cGMP) pathway and ATP-sensitive K+ channel pathway.
Values are presented as mean ± SEM (n = 5). *** p < 0.001 compared with the control group (ANOVA followed by post hoc Dunnett’s test)
Mannan et al. BMC Complementary and Alternative Medicine  (2017) 17:72 Page 10 of 13On the other hand, N-methyl-D-aspartate receptor
antagonists have been proven to inhibit the spread of
pain sensation and to decrease the hyperactive excitabil-
ity of spinal cord neurons triggered by C-fiber stimula-
tion [66, 67]. In addition, activation of glutamate
receptors also has been shown to contribute to the con-
tinuation of peripheral nociceptive processes that are
connected with inflammatory pain [68], which is concur-
rent with the report that application of glutamate recep-
tor antagonist obstructed the inflammatory phases of the
formalin test. Based on our findings, glutamatergic
system involved in the modulation of MEDS antinoci-
ception (Fig. 3 and Table 6).
In addition, recent studies have been assessed the
cinnamaldehyde-induced nociception, to investigate the
participation of TRPA1 receptor in the antinociceptive
effect of MEDS. It has shown that cinnamaldehyde acti-
vates primary afferent sensory neurons through a direct
action on TRPA1, a member of the Transient Receptor
Potential family (TRP) of cation channels that are highly
expressed by a subset of C-fibre nociceptors [69]. Cur-
rently, it was demonstrated that intraperitoneal adminis-
tration of cinnamaldehyde, a TRPA1 agonist receptor, toTable 8 Effects of D. sissoo leave extract on involvement of cyclic gu
Treatment Dose (mg/kg)
Control 0.1 mL/ mouse
Methylene Blue (MB) 20
MEDS +MB 100 + 20
MEDS +MB 200 + 20
MEDS +MB 400 + 20
Values are presented as mean ± SEM (n = 5). MEDSMethanolic extract of D. sissoo
*** p < 0.001 compared with the control group (Dunnett’s test)
** p < 0.01 compared with the control group (Dunnett’s test)mice produced a dose-dependent regular nociception
[70]. Our results show that MEDS significantly reduced
the cinnamaldehyde-induced pain (Fig. 3 and Table 7).
This result indicates that MEDS probably interacts with
the TRPA1 receptor located in C-fibres reducing the
cinnamaldehyde -induced nociception.
The present study also investigated the possible par-
ticipation of cGMP pathway on the antinociceptive
activity of MEDS (Fig. 5 and Table 8). Physiological
functions as pain and analgesia are influenced by the
cellular level of cGMP-regulated by the action of sGC
interceded by nitric oxide (NO) [71]. The cGMP path-
way depends on the synthesis and release of nitric oxide
triggered by the activation of nitric oxide-synthase
(NOS), which then activates the guanylyl synthase re-
sulted in the formation of cGMP, the most monumental
messenger of the system [72]. Therefore, cGMP seems
to be very significant for the functioning of up or down
regulation of nociceptor. Intracellular cGMP concentra-
tions are regulated by the action of GCs and by the rate
of degradation by cGMP-specific phosphodiesterases. It
has been reported that the action of cGMP on the ion
channels may be direct or through the activation ofanosine monophosphate (cGMP) pathway
Number of writhing Inhibition (%)
71.74 ± 1.77 –
58.20 ± 2.89*** 18.87
37.90 ± 0.96** 47.17
26.10 ± 1.69*** 63.62
15.90 ± 1.52*** 77.84
Table 9 Effects of D. sissoo leave extract on involvement of
ATP-sensitive K+ channel pathway
Treatment Dose (mg/kg) Number of writhing Inhibition (%)
Control 0.1 mL/ mouse 73.4 ± 1.71 –
Glibenclamide (GB) 10 62.3 ± 1.11 15.12
MEDS + GB 100 + 10 42.3 ± 2.07** 42.37
MEDS + GB 200 + 10 35.3 ± 1.45*** 51.91
MEDS + GB 400 + 10 24.2 ± 2.02*** 67.03
Values are presented as mean ± SEM (n = 5). MEDS Methanolic extract of
D. sissoo
*** p < 0.001 compared with the control group (Dunnett’s test)
** p < 0.01 compared with the control group (Dunnett’s test)
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the feasible involvement of cGMP in MEDS induced anti-
nociception, methylene blue (MB), aguanylyl cyclase and/
or nitric oxide synthase inhibitor, was administered prior
to inducing nociception with the intraperitoneal injection
of acetic acid. The result presents that the pre-treatment
with methylene blue significantly reduced the nociception
caused by acetic acid and enhanced the antinociceptive ef-
fect exerted by MEDS. It has been suggested that MB pro-
motes antinociceptive activity by inhibiting peripheral
NOS and sGC, resulting in NO interference [70]. As pre-
treatment with MB and subsequent administration of
MEDS at all doses increased antinociceptive effect in
acetic acid-induced writhing test in mice. These results
suggest that the cGMP pathways have been involved in
the antinociceptive effects of the MEDS in the acetic acid-
induced nociception in mice model.
The results also point out that the antinociceptive ef-
fect of MEDS might involve the participation of the
ATP–sensitive K+ channel pathway; glibenclamide, an
ATP–sensitive K+ channel antagonist, could partially re-
verse the antinociceptive activity of MEDS (Fig. 5 and
Table 9). Previous studies report specific blockade of
ATP-sensitive K+ channel by glibenclamide while not af-
fecting other types of K+ channel like Ca2+ activated and
voltage-gated K+ channels [74, 75]. The antinociceptive
action of MEDS might relate to ATP–sensitive K+ chan-
nel opening and the subsequent efflux of K+ ions and
membrane repolarization or hyperpolarization [76].
Conclusions
It can be concluded that MEDS possesses significant
antinociceptive activity in both chemical and heat-
induced pain models in mice. The antinociceptive effect
of MEDS is most likely mediated via inhibition of per-
ipheral mediators and central inhibitory mechanisms.
These results support the traditional use of this plant in
different painful conditions. Further investigations are
required to perceive the mechanisms of action of MEDS
and to identify the active constituents that may be used
as a lead compound for new drug development.Abbreviations
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